Affiliation:
1. Beijing Institute of Biological Products Company Limited, Beijing 100170, China
Abstract
There are some concerns about the safety of live attenuated yellow fever vaccines (YF–live), particularly viscerotropic adverse events, which have a high mortality rate. The cellular production of the vaccine will not cause these adverse effects and has the potential to extend applicability to those who have allergic reactions, immunosuppression, and age. In this study, inactivated yellow fever (YF) was prepared and adsorbed with Alum/CpG. The cellular and humoral immunities were investigated in a mouse model. The results showed that Alum/CpG (20 μg/mL) could significantly increase the binding and neutralizing activities of the antibodies against YF. Moreover, the antibody level at day 28 after one dose was similar to that of the attenuated vaccine, but significantly higher after two doses. At the same time, Alum/CpG significantly increased the levels of IFN-γ and IL-4 cytokines.
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference36 articles.
1. Yellow Fever: A Perennial Threat;Tuells;Arch. Med. Res.,2022
2. Gianchecchi, E., Cianchi, V., Torelli, A., and Montomoli, E. (2022). Yellow Fever: Origin, Epidemiology, Preventive Strategies and Future Prospects. Vaccines, 10.
3. Emerging and Re-emerging Vector-Borne Infectious Diseases and the Challenges for Control: A Review;Chala;Front. Public Health,2021
4. Systematic review: Yellow fever control through environmental management mechanisms;Heinz;Trop. Med. Int. Health,2021
5. Monoclonal antibody treats yellow fever;Crunkhorn;Nat. Rev. Drug Discov.,2023